A Reliable Global Supply of Lutetium-177
Isotopia ensures a dependable and secure supply of Lutetium-177 (Lu-177), a crucial isotope for advanced cancer therapies. The addition of Seibersdorf Laboratories in Austria as a CMO strengthens our global manufacturing network and allows us to meet the growing demand for life-saving treatments.
Proximity and Timely Patient Care
With three strategically located production facilities—in Israel, the United States, and Europe—we ensure timely and flexible product delivery for every patient, everywhere. The Seibersdorf facility, backed by EU Marketing Authorization and GMP certification, highlights our commitment to 24/7 personalized and caring service while minimizing patient risk.
Expanding Global Reach
The Seibersdorf site marks a significant milestone in our mission to make advanced cancer therapies available worldwide. By securing long-term agreements with suppliers and nuclear reactors, we guarantee an uninterrupted supply chain, thus reinforcing our ability to deliver targeted radionuclide therapy with precision and reliability.
A Commitment to Innovation and Care
Our expansion reflects Isotopia’s dedication to:
- Healthcare Providers: Supporting life-saving therapies with a continuous, dependable supply of radiopharmaceuticals.
- Patients: Advancing cancer treatment through innovative and caring solutions.
- Sustainability: Operating precisely and efficiently to meet current demands while preparing for future challenges.
Advancing Cancer Care Worldwide
Isotopia’s strategic production facilities ensure we remain at the forefront of targeted radionuclide therapy, delivering timely, dependable solutions to healthcare providers and patients worldwide. This expansion underscores our commitment to minimizing patient risk and advancing the standard of cancer treatment worldwide.
